Fig 2. Verdinexor reduces inflammatory cell infiltration into the bronchoalveolar space in influenza infected mice.

Mice were infected with 10×MID₅₀ of mouse-adapted A/California/04/09 intranasally and treated orally with 20 mg/kg verdinexor at day 1 and 3 or 10 mg/kg oseltamivir twice daily post-infection. BAL cells from day 2 and 4 post-infection were characterized using flow cytometry. Percent of CD11c+Gr-1-, CD11c+Gr-1+, CD3+, DX5+, and CD3+DX5+ cells were plotted. The data are from five mice per experimental group per time point. *, p≤0.05; **, p≤0.01; ***, p≤0.001; ****, p≤0.0001.